Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 184 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup, 2013, Candida and Candidaemia: Susceptibility and Epidemiology, Dan. Med. J.
- Disputedcites [43] Hii, 2015, Changing epidemiology of candidemia in a medical center in middle Taiwan, J. Microbiol. Immunol. Infect. sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Farahat, 2014, Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia, Int. J. Infect. Dis. source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning, D.W. (2016). Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized. Philos. Trans. R. Soc. B, 371. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao, 2014, Prevalence of infectious keratitis in Central China, BMC Ophthalmol. source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning, 2017, Calling upon all public health mycologists, Eur. J. Clin. Microbiol. Infect. Dis. sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown, 2012, Hidden Killers: Human Fungal Infections, Sci. Transl. Med. source
- Partly supportedcites [2] Denning, D.W. (2016). Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized. Philos. Trans. R. Soc. B, 371. sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Meintjes, 2014, A neglected epidemic: Fungal infections in HIV/AIDS, Trends Microbiol. source
- Not checked — no full text of the sourcecites [4] Guinea, 2010, Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome, Clin. Microbiol. Infect. source
- Not checked — no full text of the sourcecites [5] Marr, 2002, Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors, Blood source
- Not checked — no full text of the sourcecites [6] Limper, A.H., Adenis, A., Le, T., and Harrison, T.S. (2017). Fungal infections in HIV/AIDS. Lancet Infect. Dis. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning, 2013, Global fungal Burden, Mycoses, 56, 13
- The Fungal Infection Trust (2011, January 18). How common are fungal diseases?. Proceedings of the Fungal Research Trust 20th Anniversary Meeting, London, UK. Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf.
- Jayasekera, 2013, The burden of serious fungal infections in Sri Lanka, Mycoses, 56, 103
- Gugnani, 2017, Burden of serious fungal infections in Bangladesh, Eur. J. Clin. Microbiol. Infect. Dis., 36, 965, 10.1007/s10096-017-2921-z · DOI · Paper page
- Samayoa, B., Isern, V., Serra, L., Rivera, B.E., Nikiforov, M., Arathoon, E., Samayoa, C., Vallès, X., Prieto, L., and Álvarez, C. (2010, January 18–23). Preliminary results of a prospective cohort of HIV+ patients in Guatemala. Proceedings of the XVIII International AIDS Conference, Vienna, Austria.
- Gopinathan, 2002, The Epidemiological Features and Laboratory Results of Fungal Keratitis, Eye, 21, 555
Cited by
Items 1,601–1,700 of 2,931
Histoplasma and Histoplasmosis
Bongomin, F. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.87271 · Cited by 5
Self-citationGÜLBUDAK, H., Öztürk, C., Kuyugöz, S., & Ülger, S. T. (2020) · Mikrobiyoloji Bulteni · doi:10.5578/mb.69853 · Cited by 5
Oon, Y. N. (2021) · Tropical biomedicine · doi:10.47665/tb.38.3.090 · Cited by 8
Antifungal activity of [K3]temporin-SHa against medically relevant yeasts and moulds
Brunet, K., Verdon, J., Ladram, A., Arnault, S., Rodier, M., & Cateau, E. (2022) · Canadian Journal of Microbiology · doi:10.1139/cjm-2021-0250 · Cited by 9
Debta, P., Swain, S. K., Sahu, M. C., Abuderman, A., Alzahrani, K. J., Banjer, H. J., Qureshi, A. A., Bakri, M. M. H., Sarode, G. S., Patro, S., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19148510 · Cited by 69
Unmet needs and practical solutions in the management of invasive mould infections in Asia
Chen, Y., Chayakulkeeree, M., Chakrabarti, A., Gan, G. G., Kwong, Y., Liu, W., Tan, B. H., & Todi, S. K. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac251 · Cited by 7
Drug Resistance and Evolvability in an Emerging Human Fungal Pathogen
Billmyre, R. B. (2022) · mBio · doi:10.1128/mbio.01876-22 · Cited by 5
de Oliveira, T. E., Greatti, V. R., Sorrechia, R., & Pietro, R. C. L. R. (2022) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001575 · Cited by 6
Desmarini, D., Truong, D., Wilkinson‐White, L. E., Deshpande, C. N., Torrado, M., Mackay, J. P., Matthews, J. M., Sorrell, T. C., Lev, S., Thompson, P. E., et al. (2022) · Biomolecules · doi:10.3390/biom12101526 · Cited by 5
“5 million deaths annually around the world, matching deaths from tuberculosis and exceeding those from malaria [1,2].”
BackgroundNanoliposomes as Drug Delivery Systems for Antifungal Therapy
Alobeidat, S., & Athamneh, T. (2022) · Precision Nanomedicine · doi:10.33218/001c.56154 · Cited by 5
Cao, C., Wang, Y., Avina, S. L., Walter, J., & Xue, C. (2022) · Journal of Fungi · doi:10.3390/jof8121259 · Cited by 7
“5 million people each year and are a significant global public health burden [1].”
BackgroundCould the Lung Be a Gateway for Amphotericin B to Attack the Army of Fungi?
Patricio, B. F. D. C., Pereira, J. O. D. S. L., Sarcinelli, M. A., de Moraes, B. P. T., Rocha, H. V. A., & Gonçalves-de-Albuquerque, C. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122707 · Cited by 5
“In addition, opportunistic fungi such as Coccidioides, Paracoccidioides, Candida, Sporothrix, and Histoplasma can cause severe lung infections that progress to dissemination, affecting other tissues and surpassing a million cases worldwide [5,6].”
BackgroundInfluentialZhan, L., Tian, X., Lin, J., Peng, X., & Zhao, G. (2023) · Current Eye Research · doi:10.1080/02713683.2022.2164779 · Cited by 5
“It is estimated that there are 1 million cases annually worldwide, and more than 80% of cases are in developing countries.(1,4) In developed countries, an outbreak of FK in contact lens wearers came to public attention in 2005.”
BackgroundSecondary invasive fungal infection in hospitalised patients with COVID ‐19 in the United States
Thompson, G. R., Miceli, M. H., Jiang, J., Shortridge, E. F., Davies, K., Gurumoorthy, G., & Kimura, T. (2023) · Mycoses · doi:10.1111/myc.13579 · Cited by 7
Kibwana, U. O., Manyahi, J., Kamori, D., Mushi, M. F., Mwandigha, A. M., & Majigo, M. V. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-070003 · Cited by 5
Nanomedicines for the Treatment of Systemic Candidiasis
Rana, D., Salave, S., Rawat, G., & Benival, D. M. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-39020-3_4 · Cited by 6
Xu, S., Lu, S., Gu, Y., Sun, H., Ma, M., Leng, Y., & Liu, W. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1285753 · Cited by 5
Ahmadi, M., Shahbahrami, R., Khajeh, F., et al. (2023) · Acta Histochemica · doi:10.1016/j.acthis.2023.152116 · Cited by 5
Sri, V. L. P., Srinivasan, S., Muthukumar, S., Sreeja, C., Nachiammai, N., & Thamilselvan, S. (2023) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/jomfp.jomfp_273_23 · Cited by 5
“[4] Candidiasis is the most common fungal infection caused by causative C. albicans predominantly along with C. tropicalis , C. glabrata , C. parapsilosis , C. guillermondii , C. krusei , C. Kiefer , and C. dubliniensis.”
BackgroundMethodTaher, K. W., Almofada, R., Alomair, S. M., Albassam, A. A., & Alsultan, A. (2024) · Pediatric Drugs · doi:10.1007/s40272-023-00616-4 · Cited by 5
“For example, the incidence of invasive aspergillosis worldwide has risen lately to > 300,000 cases from the previously reported 200,000 cases, with an associated mortality rate of 30–80% [6].”
Molecular Study of Pneumocystis jirovecii in Respiratory Samples of HIV Patients in Chile
Iturrieta‐González, I., Chahín, C., Cabrera, J., Concha, C., Olivares-Ferretti, P., Briones, J., Vega, F., Medina, L., & Fonseca-Salamanca, F. (2024) · Journal of Fungi · doi:10.3390/jof10020117 · Cited by 7
“…because it is a microorganism that does not grow in culture media, and its detection is generally carried out by microscopic observation of trophic or cystic forms in respiratory samples with cytochemical or immunofluorescence staining, a method that presents a sensitivity close to 90% [10].”
BackgroundYao, Q., He, Y., Deng, L., Chen, D., Zhang, Y., Hui, L., & Wei, L. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09212-4 · Cited by 6
“Older individuals and patients with chronic respiratory diseases are susceptible to respiratory fungal colonization and invasion [2].”
BackgroundCryptococcus neoformans and cryptococcosis: a contribution made by Prof. Dr. Mahendra Pal
Pal, M. S. (2024) · Journal of Bacteriology & Mycology Open Access · doi:10.15406/jbmoa.2024.12.00368 · Cited by 5
The incidence and prevalence of serious fungal diseases in Tunisia
Fathallah, A., Chouaieb, H., Saief, M. B., Ismaïl, S., Saïd, M. B., & Denning, D. W. (2024) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2024.101479 · Cited by 6
“Until recently it was thought that about 2 million people die from invasive fungal infections each year in the world; this estimate has been updated to about 3.8 million [1 − 3].”
BackgroundInfluentialSelf-citationNew Multi-View Feature Learning Method for Accurate Antifungal Peptide Detection
Ferdous, S. M., Mugdha, S. B. S., & Dehzangi, A. (2024) · Algorithms · doi:10.3390/a17060247 · Cited by 5
“Fungal infections pose a significant threat to human health, affecting over one billion people worldwide annually [1].”
BackgroundBasuli, F., Shi, J., Shah, S., Lai, J., Hammoud, D. A., & Swenson, R. E. (2024) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4116 · Cited by 5
The synergistic effect of photodynamic and sonodynamic inactivation against Candida albicans biofilm
Guimarães, G. G., Alves, F., Gonçalves, I. S., Carvalho, I. S. E., Ayala, E. T. P., Pratavieira, S., & Bagnato, V. S. (2024) · Journal of Biophotonics · doi:10.1002/jbio.202400190 · Cited by 6
Tian, Y., Luan, J., Wang, Q., et al. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00123 · Cited by 5
Storer, I. S. R., Sastré-Velásquez, L. E., Easter, T., Mertens, B., Dallemulle, A., Bottery, M. J., Tank, R. K. J., Offterdinger, M., Bromley, M., van Rhijn, N., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00803-24 · Cited by 7
Ludwig, D. B., de Camargo, L. E. A., Tominaga, T. T., & Mainardes, R. M. (2024) · BioNanoScience · doi:10.1007/s12668-024-01614-7 · Cited by 5
“Fungal infections pose a significant global health challenge, particularly affecting millions of people worldwide and imposing a heavy burden on public health systems, especially in hospitalized patients [1, 2].”
Zhang, X., Lu, B., Yang, S., Lin, B., Chen, G., Wang, L., Peng, Z., Lü, H., Wang, C., Li, D., et al. (2025) · Environment & Health · doi:10.1021/envhealth.4c00195 · Cited by 6
Ahmed, A., Mohamed, N. S., & Siddig, E. E. (2025) · Journal of Fungi · doi:10.3390/jof11080569 · Cited by 8
“With approximately one billion individuals affected by fungal diseases each year, resulting in an estimated 1.5 million deaths, the impact of these infections is profound [4].”
InfluentialInternal and external quality control in the medical microbiology laboratory
Fowotade, A., Fayemiwo, S. A., Bongomin, F., Fasuyi, T. O., Aigbovo, O. A., & Adegboro, B. (2018) · African Journal of Clinical and Experimental Microbiology · doi:10.4314/ajcem.v19i4.1 · Cited by 4
Self-citationAranda‐Audelo, M., Rivera-Martínez, N. E., & Corzo-León, D. (2018) · Journal of Fungi · doi:10.3390/jof4030109 · Cited by 5
“Previous estimates have shown that IFIs cause as many deaths as tuberculosis and malaria [8,9].”
BackgroundTreating Fungal Keratitis with Oral Voriconazole Only: A Case Series
Chen, D., Tan, S., & Zou, W. (2020) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1268-9168 · Cited by 5
“According to reports in the literature, more than one billion people worldwide may suffer from fungal diseases [11].”
BackgroundCANDIDA DIAGNOSTIC PLATFORMS: ESSENTIAL IN EARLY MANAGEMENT OF CANDIDA INFECTIONS
Hassan, Y., Aminu, I., & Abbdullahi, S. A. (2021) · FUDMA Journal of Sciences · doi:10.33003/fjs-2021-0502-522 · Cited by 6
Mucormycosis or black fungus: An emerging threat in COVID-19
Bhadra, A., Ahmed, M. S., Rahman, M. A., & Islam, S. (2021) · Bangabandhu Sheikh Mujib Medical University Journal · doi:10.3329/bsmmuj.v14i3.54682 · Cited by 7
Aspergillus PJI – A systematic analysis of all known cases and report of a new one
Karczewski, D. C., Khakzad, T., Kriechling, P., et al. (2021) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2021.101141 · Cited by 5
Scharf, S. A., Bartels, A., Kondakci, M., Haas, R. R., Pfeffer, K., & Henrich, B. (2021) · Medical Mycology · doi:10.1093/mmy/myab045 · Cited by 7
Pathogenicity Mechanism of Candida albicans
Pattnaik, S., Maharana, L., & Sethi, M. (2021) · Infectious diseases · doi:10.5772/intechopen.99737 · Cited by 9
Characterization and concentration of airborne fungi in public transport vehicles in Istanbul
Metiner, K., Kekeç, A. I., Halaç, B., BAĞCIGİL, A. F., Maslak, B., Sivri, N., & Onat, B. (2021) · Arabian Journal of Geosciences · doi:10.1007/s12517-021-08643-6 · Cited by 5
“Their presence reduces the IAQ of buildings and affect building occupant’s well-being, causing health problems (Bongomin et al. 2017; Casadevall 2018).”
BackgroundImpact of Toxigenic Fungi: An Economic and Health Obstruction to Wellness in Mozambique
Fernandes, T. H., Ferrão, J., Guina, J. A., Chabite, I. T., Garrine, C. M. L. P., & Bell, V. (2021) · European Journal of Agriculture and Food Sciences · doi:10.24018/ejfood.2021.3.5.392 · Cited by 5
“Other fungal infections occurring presently in India and Brazil [44], yet unidentified in Mozambique but in need of investigation, are the fungal opportunistic, uncommon but serious infection, from Rhizopus oryzae, that can be devastating in cases of Covid-19-associated pulmonary mucormycosis, as it is usually found i…”
BackgroundFunctions and inhibition of BET bromodomains in pathogenic fungi
Sayou, C., & Govin, J. (2022) · Current Opinion in Green and Sustainable Chemistry · doi:10.1016/j.cogsc.2022.100590 · Cited by 6
Bankaitis, V. A., Tripathi, A., Chen, X., & Igumenova, T. I. (2022) · Advances in Biological Regulation · doi:10.1016/j.jbior.2022.100891 · Cited by 6
Bryant, J. A., Riordan, L., Watson, R., Nikoi, N. D., Trzaska, W. J., Slope, L. N., Tibbatts, C., Alexander, M. R., Scurr, D. J., May, R. C., et al. (2022) · Global Challenges · doi:10.1002/gch2.202100138 · Cited by 5
Qiao, L., Cui, X., Jia, L., Gao, Y., Wang, W., Wei, F., Zhang, Z., Chen, D., Ma, Y., & Zhang, Y. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108985 · Cited by 7
Sullivan, B. N., Baggett, M. A., O’Connell, S. S., Pickett, K., & Steele, C. H. (2022) · Journal of Fungi · doi:10.3390/jof8070722 · Cited by 6
“IPA is diagnosed in more than 300,000 immunocompromised patients annually and is associated with a 30–80% mortality rate [2,15,16].”
BackgroundNguyen, P. T., Wacker, T., Brown, A. J. P., Dantas, A. D. S., & Shekhova, E. (2022) · Journal of Fungi · doi:10.3390/jof8070736 · Cited by 6
“Fungal infections affect hundreds of millions of people globally each year [1].”
BackgroundBhargav, A., Fatima, F., Chaurasia, P., Seth, S., & Ramachandran, S. (2022) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2021.0039 · Cited by 5
Real world co‐prescribing contraindicated drugs with fluconazole and itraconazole
Je, N. K., Youm, S., & Chun, P. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5604 · Cited by 5
“17 billion people worldwide have fungal diseases, while 1 billion are estimated to have dermatophytosis.(1) In South Korea, 3.”
BackgroundGong, X., Srivastava, V., Naicker, P., Khan, A., & Ahmad, A. (2023) · Vaccines · doi:10.3390/vaccines11030674 · Cited by 7
“Candidiasis often results in blood infection (candidemia), which has a high mortality rate of above 40% [1,2].”
BackgroundRivera, A., Lim, W. Y., Park, E., Dome, P. A., Hoy, M. J., Spasojević, I., Sun, S., Averette, A. F., Piña‐Oviedo, S., Juvvadi, P. R., et al. (2023) · mBio · doi:10.1128/mbio.01810-23 · Cited by 6
“Additionally, cryptococcal infections are associated with high mortality, and the treatment options for the population most devastated by this human fungal pathogen are typically limited to orally available but fungistatic fluconazole (1, 3).”
BackgroundInfluentialFonseca, S. N. S. (2024) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001327 · Cited by 7
Puumala, E., Sychantha, D., Lach, E., Reeves, S., Nabeela, S., Fogal, M., Nigam, A., Johnson, J. W., Aspuru‐Guzik, A., Shapiro, R. S., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.01.010 · Cited by 7
Azole-resistant Candida albicans Spondylodiscitis After Bariatric Surgery
Silva, M. R., Pinho, A. R., Vital, L., et al. (2020) · JBJS Case Connector · doi:10.2106/jbjs.cc.19.00618 · Cited by 5
What is the elephant in the room when considering new therapies for fungal diseases?
Chaves, A. F. A., Xander, P. B., Romera, L. M. D., Fonseca, F. L. A., & Batista, W. L. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1876632 · Cited by 5
“The prevalence of pneumonia caused by Pneumocystis jiroveci is highest in Nigeria, with astounding 48.2 cases per 100 000 inhabitants (Bongomin et al. 2017), while mycetoma is a major health problem in Sudan, where more than 7000 patients are receiving treatment and where 70% of the mycetoma cases…”
BackgroundInfluentialDarwish, R. M., Alkawareek, M. Y., Bulatova, N., & Alkilany, A. M. (2021) · Letters in Applied Microbiology · doi:10.1111/lam.13560 · Cited by 5
“Although fungal drug resistance does not seem to be as much of a problem as bacterial resistance, severe fungal infections affect substantial number of people globally leading to death in many cases (Kim et al. 2009; Bongomin et al. 2017).”
BackgroundMoya‐Salazar, J., Salazar-Hernández, R., Rojas-Zumarán, V., & Quispe, W. (2019) · Journal of Infectiology · doi:10.29245/2689-9981/2018/2.1132 · Cited by 6
dos Reis, T. F., de Castro, P. A., Bastos, R. W., Pinzan, C. F., Souza, P. F. N., Ackloo, S. Z., Hossain, M. A., Drewry, D. H., Alkhazraji, S., Ibrahim, A. S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.28.509882 · Cited by 5
Chen, Y., Stewart, J. I. P., Liu, S., Sheppard, D. C., Lu, L., & Zhang, S. (2022) · Applied and Environmental Microbiology · doi:10.1128/aem.01535-21 · Cited by 14
“able antifungal agents, the mortality rate for invasive aspergillosis (IA) ranges between 50 and 95% (2, 3).”
BackgroundCombined ImmunoCAP and Western Blot for the Diagnosis of Aspergillus Lung Disease
Petit, E., Cortaredona, S., Sicco, S., Ranque, S., & Menu, E. (2025) · Mycoses · doi:10.1111/myc.70058 · Cited by 4
Deshkar, S. S., Vas, A., Pagar, R. R., Giram, P. S., Thomas, A. B., & Undale, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050622 · Cited by 5
“Pulmonary aspergillosis impacts around 3 million individuals globally, with Asia bearing a disproportionately high impact compared to other regions [3,4].”
Yan, K., Chen, Y., Zhao, M., Li, Y., & He, J. (2025) · Atmosphere · doi:10.3390/atmos16060641 · Cited by 6
Virulence Factors and Molecular Identification of Candida Species Causing Candidemia in Honduras
Chávez, J. F., Ortíz, B., López, R., Muñoz, C., Aguilar, K., Laínez-Arteaga, I., Galindo, C., Rivera, L. E., Ballesteros‐Monrreal, M. G., Montes, K., et al. (2025) · Journal of Fungi · doi:10.3390/jof11070470 · Cited by 4
Does the use of topical azoles have an impact on antifungal resistance?
Maillard, J. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf270 · Cited by 7
Benwan, K. A., Ahmed, S. A., Banwan, D. A., & John, M. (2025) · Journal of Fungi · doi:10.3390/jof11090670 · Cited by 6
“It is associated with high morbidity and mortality rates, particularly among critically ill and immunocompromised patients [1,2].”
An overview of the mechanistic approaches of antifungal nanomaterials
Saha, S., Павловна, С. Н., Gurina, R., NEBORAK, E. V., Zhabo, N., Avdonina, M., & Molchanova, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1701446 · Cited by 5
Cao, Y., Li, Y., Wang, M., Wu, Y., Shi, S., Wang, C., Gao, Z., Yang, W., Wang, L., & Kang, H. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1658476 · Cited by 7
Pulmonary Fungal Infections in the Immunocompetent Host
Lieu, A., Mah, J., Vinh, D. C., & Qureshi, S. T. (2026) · CHEST Journal · doi:10.1016/j.chest.2025.12.041 · Cited by 4
Mamaghani, K. R., Alikarami, M., Saremi, H., & Parvin, N. (2026) · IET Nanobiotechnology · doi:10.1049/nbt2/7866252 · Cited by 5
Fung-AI: An AI/ML-driven pipeline for antifungal peptide discovery
Berman, D., Lewis, E. A., Curtis, T. D., Tiburzi, O. N., Smith, D. F. Q., Casadevall, A., & Dunphy, L. J. (2026) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1014105 · Cited by 5
A computational approach to identify novel plant metabolites against Aspergillus fumigatus
Ahmed, J., Raihan, M. M., Robin, T. B., Sami, M. R. S., Mahfuz, S., Haque, N., Akter, H., Bappy, M. N. I., Afrin, D., & Moli, M. A. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101385 · Cited by 4
Li, L., Fang, J., Li, J., et al. (2024) · Mycopathologia · doi:10.1007/s11046-024-00837-2 · Cited by 4
Jung, Y. J. (2024) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2024.01.006 · Cited by 4
Rumex japonicus Houtt. leaves: the chemical composition and anti-fungal activity
Xiao, D., Sun, H., Li, X., Meng, F., Sun, T., Shao, X., Ding, Y., & Li, Y. (2024) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2024.101513 · Cited by 7
Mammalian Pattern Recognition Receptors (PRRs) Involved in Recognition of Fungi
Sey, E. A., Willment, J. A., & Brown, G. D. (2024) · The mycota · doi:10.1007/978-3-031-64853-3_8 · Cited by 4
Pea Protein Isolate-Based Nanofibers for Delivery of Clotrimazole
Kalouta, K., Stie, M. B., Vetri, V., & Foderà, V. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c05989 · Cited by 4
The putative error prone polymerase REV1 mediates DNA damage and drug resistance in Candida albicans
Agyare-Tabbi, M. R., Uthayakumar, D., Francis, D., Maroc, L., Grant, C., McQueen, P., Westmacott, G., Shaker, H., Skulska, I., Gagnon‐Arsenault, I., et al. (2024) · npj Antimicrobials and Resistance · doi:10.1038/s44259-024-00057-0 · Cited by 8
Impact of inter-species hybridisation on antifungal drug response in the Saccharomyces genus
Visinoni, F., Royle, W., Scholey, R., Hu, Y., Timouma, S., Zeef, L. A. H., Louis, E. J., & Delneri, D. (2024) · BMC Genomics · doi:10.1186/s12864-024-11009-3 · Cited by 8
“The tally of life-threatening infections associated with fungal pathogens is estimated to be on the same scale as tuberculosis and malaria with 13 million infections yearly, and a mortality of 1.5 million (Bongomin et al. 2017; Fisher et al. 2018).”
BackgroundInfluentialYu, P., Ye, S., Zhou, M., Zhang, L., Zhang, Z., Sun, X., Li, S., & Hu, C. (2024) · mSphere · doi:10.1128/msphere.00703-24 · Cited by 5
Franconi, I., Fais, R., Giordano, C., Tuvo, B., Stani, C., Tavanti, A., Barnini, S., & Lupetti, A. (2025) · Journal of Fungi · doi:10.3390/jof11010040 · Cited by 6
Hu, X., Du, M., Tao, C., Wang, J., Zhang, Y., Jin, Y., & Yang, E. (2025) · PLoS Genetics · doi:10.1371/journal.pgen.1011482 · Cited by 6
Balaeş, T., Mangalagiu, V., Antoci, V., Amăriucăi-Mantu, D., Diaconu, D., & Mangalagiu, I. I. (2025) · Pharmaceuticals · doi:10.3390/ph18040495 · Cited by 6
Wiesner, A., Zagrodzki, P., & Paśko, P. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01511-6 · Cited by 4
“Additionally, skin infections caused by Candida species and dermatophytes, along with chronic fungal respiratory infections, affect nearly one billion people worldwide and may significantly impair quality of life [6].”
Obermeier, M., Esparza-Mora, M. A., Heese, O., Cohen, N., Varma, S. J., Tober‐Lau, P., Hartl, J., Kurth, F., Berman, J. G., & Ralser, M. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002046 · Cited by 4
“Fungal infections represent a substantial medical challenge, affecting more than one billion people globally [1].”
Climate Change and Dermatologic Diseases in the Global South
Enbiale, W. (2025) · Dermatologic Clinics · doi:10.1016/j.det.2025.08.004 · Cited by 6
Heterochromatin epimutations impose mitochondrial dysfunction to confer antifungal resistance
Fellas, A., Pidoux, A. L., Tong, P., Hewes, H. H., Wallace, E. C., & Allshire, R. C. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00649-0 · Cited by 6
“Fungal infections cause over 1.5 million human deaths annually (Bongomin et al, 2017).”
InfluentialFungal Diseases and Their Treatment: A Holistic Approach
Kumar, S., Jain, T., & Banerjee, D. (2019) · Springer eBooks · doi:10.1007/978-981-32-9449-3_6 · Cited by 9
Signaling Pathways Governing the Caspofungin Paradoxical Effect in Aspergillus fumigatus
Papon, N., Morio, F., & Sanglard, D. (2020) · mBio · doi:10.1128/mbio.01816-20 · Cited by 5
“Of these, invasive infections caused by the mold Aspergillus fumigatus which occur in immunocompromised patients, and especially neutropenic or solidorgan transplant recipients, are responsible for up to 100,000 deaths a year worldwide (2).”
BackgroundAdverse Drug Reactions in Drug-Resistant Tuberculosis Management: A Clinical Approach
Babu, L. P., Babu, J. V., George, S., Robin, N., & Jose, J. (2021) · Indian Journal of Pharmacy Practice · doi:10.5530/ijopp.14.2.16 · Cited by 4
Tonui, J., Mureithi, M., Jaoko, W. G., & Bii, C. C. (2021) · Pan African Medical Journal · doi:10.11604/pamj.2021.38.227.26485 · Cited by 5
“The big challenge in management of pulmonary fungal infections is emerging triazole resistance especially among the Aspergillus fumigatus [1, 10].”
BackgroundDutta, A., Ikwuezunma, A., Castellanos, M. I., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29228 · Cited by 4
Valero, C., Colabardini, A. C., de Castro, P. A., Silva, L. P., Ries, L. N. A., Pardeshi, L. A., Wang, F., Rocha, M. C., Malavazi, I., Silva, R. N., et al. (2021) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2021.689900 · Cited by 4
“Invasive pulmonary aspergillosis is the most common human systemic infection caused by filamentous fungi (Brown et al., 2012; Bongomin et al., 2017).”
BackgroundAnalysis of the retail range of antifungal medicines using an integrated ABC-XYZ analysis matrix
Krylova, O., Rozhnova, S. A., Tananakina, G., Мариевский, В. Е., Magomedova, Z., & Magomedova, R. (2021) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/gjqhlvqgne · Cited by 32
“No less severe mycotic infections, such as pneumocystis pneumonia, affect about 500,000 people annually, invasive aspergillosis and disseminated histoplasmosis-250,000 and 3100,000 people, respectively [3, 4].”
BackgroundFungal Infection: A Recent Concern for Physician
Ahasan, H. N., & Noor, N. (2022) · Bangladesh Journal of Medicine · doi:10.3329/bjm.v33i3.61367 · Cited by 4
“Specifically, the growing prevalence of fungal infections is directly associated with ever-increasing rates of (1) medical vulnerabilities, including immunosuppression due to HIV/AIDS, hematologic cancers and cancer chemotherapeutics, the use of immuno-suppressive agents for organ and bone marrow transplantation, and…”
BackgroundHirose, D., Watanabe, K., Hagiuda, R., Tachikawa, R., Kamijo, T., Yaguchi, T., & Hirota, M. (2022) · Medical Mycology Journal · doi:10.3314/mmj.22-00017 · Cited by 4
Ocaña-Ortega, A., Pérez‐Flores, G., Torres‐Tirado, D., & Pérez-García, L. A. (2023) · Journal of Fungi · doi:10.3390/jof9020141 · Cited by 5
“It has also been shown that certain sectors of the population (older adults and newborns) are more prone to these fungal infections; this is because elderly people have a weakened immune system, and something similar happens in newborns, who still have a developing immune system [3,4].”
BackgroundUse of drugs not listed in the National List of Essential Medicines
Jhaj, R., Banerjee, A., Kshirsagar, N., et al. (2022) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_878_21 · Cited by 4
“[29] Moreover, there has been an increase in the burden of dermatophytosis in recent years, for which terbinafine and itraconazole are recommended as systemic antifungals by the Indian Expert Forum Consensus Group.”
Sui, X., Cheng, X., Li, Z., Wang, Y., Zhang, Z., Yan, R., Chang, L., Li, Y., Xu, P., & Duan, C. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.194953 · Cited by 5
Chemistry and Antifungal Activity of Homoisoflavonoids
Ferreira, A. R., & de Sousa, D. P. (2023) · Journal of Chemistry · doi:10.1155/2023/1223690 · Cited by 4
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.